Carbapenem Resistant Enterobacterales (CRE) treatment: do multinational observational studies help?

This keynote lecture was presented at the 32nd International Congress of Antimicrobial Chemotherapy (ICC) in Perth, Australia.

With carbapenem resistance increasing among Enterobacterales, Prof. Kanj addresses what we know from multinational observational studies and whether they guide us in our therapy.

Prof. Souha S. Kanj (ISAC President Elect) is currently a tenured Professor of Medicine, Associate Vice President for Global Affairs, Head of the Division of Infectious Diseases, Chair of the Infection Control and Prevention Program and Co-chair of the Antimicrobial Stewardship (AMS) Program at the American University of Beirut (AUB) Medical Center, Beirut, Lebanon.

00:00 Start
00:10 Introduction
00:39 Trends in carbapenem resistance
03:14 COVID-19 and AMR
04:36 Treatment strategies for improving patient outcomes
08:33 Meropenem-vaborbactam
10:57 Ceftazidime-avibactam
23:30 What have we learned from real-world studies?
24:39 How do we achieve the best outcomes for patients with CRE infection?